Tianjin, China

Xiaoyan Dong

USPTO Granted Patents = 2 

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2014-2018

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Xiaoyan Dong: Pioneering Advances in Protein Refolding and Virus Capsomer Separation

Introduction

Xiaoyan Dong is a notable inventor based in Tianjin, China. He has made significant contributions to the fields of biochemistry and molecular biology. With a total of 2 patents, his work focuses on innovative methods for protein refolding and the development of affinity peptide ligands.

Latest Patents

Xiaoyan Dong's latest patents include two groundbreaking inventions. The first patent is titled "Affinity peptide ligand of mouse polyoma virus capsomer and designed screening method thereof." This invention provides affinity peptide ligands that can be utilized for the separation and purification of capsomers. The second patent is "Method of protein refolding with ion exchange resins and the application of the same." This method outlines a systematic approach to refolding denatured proteins using ion exchange resins, enhancing the efficiency of protein recovery.

Career Highlights

Xiaoyan Dong is affiliated with Tianjin University, where he conducts his research and development activities. His work has garnered attention for its practical applications in biotechnology and pharmaceuticals. His innovative methods are paving the way for advancements in protein engineering and viral research.

Collaborations

Xiaoyan Dong collaborates with esteemed colleagues, including Yan Sun and Lin Zhang. Their combined expertise contributes to the success of their research initiatives and enhances the impact of their inventions.

Conclusion

Xiaoyan Dong's contributions to the field of biochemistry through his patents demonstrate his commitment to innovation. His work not only advances scientific understanding but also has practical implications for various industries.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…